Eli Lilly & Co. (NYSE:LLY) - Page 2

Bull and Bear

Top Analyst Upgrades and Downgrades: Bankrate, Eli Lilly, Embraer, Oracle, Southwest Air and More

Stocks were higher on Thursday morning as investors start to move past Greece and think about a Federal Reserve that still looks somewhat dovish. The one path that keeps emerging ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Arista, Baidu, Chevron, Lexmark, Occidental, Salesforce and More

Stocks were up very marginally on Wednesday ahead of what is expected to be a no-rate-hike day from the Federal Reserve. The Greek issues are becoming less of an issue as ...
Read Full Story »
New Netflix Logo

5 Top Performers for the Past Week

Over the course of the past week, the S&P 500 and the Dow Jones Industrial Average rose have gone up and down, ending about flat on the week compared to ...
Read Full Story »
Prescription drugs

Autoimmune Drugs to Drive Big Pharma Higher in Coming Years

Credit Suisse sees some solid upside in big pharma in the coming years. After the health care sector has made a strong run, this firm believes that it can continue, ...
Read Full Story »
Eli Lilly Logo

Jefferies Makes Changes to Top Pharmaceutical Stocks to Buy

With major mergers and acquisition deals happening, and a host of clinical trials that could offer some outstanding breakthrough drug treatments, the big pharmaceutical stocks have had their fair share ...
Read Full Story »
Prescription drugs

Top Credit Suisse Major Pharma Stock Picks to Buy

Considering the health care sector has been on fire for the first quarter of 2015, analysts are putting more value in biotechs and big pharmaceuticals. Credit Suisse is no different. ...
Read Full Story »
investing

3 Surprising Overlooked Stocks That Could Have Big Upside

If there is one thing Wall Street has been guilty of over the years, it is a sort of herd mentality. This that leads to “overcrowded” trades, where everybody is ...
Read Full Story »
Pills

3 Big Pharmaceutical Stocks Will Have Rising Q1 Earnings

One thing investors look for in an aging bull market, especially one trading near all-time highs, is rising earnings. That is the only way to justify multiples that creep up ...
Read Full Story »
Prescription drugs

4 Big Pharmaceutical Stocks to Buy for the Rest of 2015

While most people consider big pharmaceutical stocks very defensive, the fact of the matter is that they offer investors terrific growth and income possibilities, which can lead to outstanding total ...
Read Full Story »
generic drugs

4 Pharmaceutical Stocks to Buy for Outperformance in 2015

It is a nice change sometimes when the prognosticators on Wall Street, who tend to follow each other's lead, are not only right, but investors come out on top. Almost ...
Read Full Story »
Pills

4 Top Pharmaceutical Stocks to Buy for Market Safety

Tuesday's big downward move reminded everybody that while things look encouraging for the stock market long term, momentum stocks tend to get absolutely eviscerated when a big volatility jump helps ...
Read Full Story »
Pfizer logo

Jefferies 4 Top Pharmaceutical Stocks to Buy

With the stock market hitting all-time highs, many investors are starting to wonder which sectors still hold value. Although seeming rich, the market continues climbing a wall of worry to ...
Read Full Story »
Pills

Large Cap Pharmaceutical Stocks to Buy Despite Negative Pricing Headlines

If there is one thing that the pharmaceutical industry tries to shy away from it is the controversy over the costs of some of the drugs on the market today. ...
Read Full Story »
investor research

Top Analyst Upgrades and Downgrades: Apple, Barrick Gold, Corning, Groupon, Peabody, SolarCity and More

Stocks were mixed on Thursday after two days of losses. While sell-offs have been sharp and out of the blue, investors have time and again shown that they will buy stocks on ...
Read Full Story »
Pills

5 Top Pharmaceutical Stock Picks for 2015

After an outstanding 2014, the health care sector could be primed for yet another solid performance in 2015. While many analysts on Wall Street are very positive on the group, ...
Read Full Story »